Viatris raises 2026 guidance across key metrics after Q3 beat street views (VTRS:NASDAQ)
Viatris reported Q3 Non-GAAP EPS of $0.71, beating estimates by $0.07, while revenue of $3.75B missed by $40M. The company raised its FY2026 adjusted EPS guidance to $2.56-$2.63 and revenue guidance to $14.7B-$14.9B, according to the company.
How this was made
The 30-second read
Why it matters
The earnings beat combined with an upward guidance revision provides a fresh catalyst for the stock.
Market read
First report of FY2026 guidance lift; material for traders targeting healthcare equities.
What to watch
Potential cost pressures or regulatory hurdles not addressed in the release.
Background
Viatris reported Q3 non‑GAAP EPS of $0.71, beating estimates, while revenue slightly missed.
Ticker impact
Viatris raised FY2026 adjusted EPS guidance to $2.56‑$2.63 and revenue guidance to $14.7‑$14.9 B, both above consensus.
upward pressure as market prices in higher earnings expectations
Guidance lift exceeds consensus and follows a beat on Q3 EPS, providing fresh, material information.
Market effects
Improves outlook for the generic pharmaceuticals sector, may lift peers.
Positive for US healthcare stocks.
Limited to pharma investors; no broad market effect.
Counterpoint
Guidance may be optimistic; execution risk could lead to a miss later.
Key entities
- CompanyViatris
Global generic pharmaceuticals manufacturer.
